AzTrials
AzTrials

Stroke, AcuteCOMPO-CLOTNCT03268668

Thrombus Composition in Ischemic Stroke: Analysis of the Correlation With Plasma Biomarkers, Efficacy of Treatment, Etiology and Prognosis

An observational study of Stroke, Acute and Biological Specimen Banks, run by Fondation Ophtalmologique Adolphe de Rothschild at 12 sites in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The recent validation of thrombectomy in addition to thrombolysis with intravenous administration of alteplase suggests a major revolution in the management of acute strokes. This treatment option also opens up a new field of research, making possible the analysis of the clot responsible for intracranial occlusion. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Collection of thrombus that is responsible for stroke and blood sample
How many people
1,200 participants
Where
12 sitesFrance
Study dates
13 Jul 2017to 1 Jan 2028
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adult patients with ischemic stroke

Who may be able to join

  • Patients aged 18 years and older
  • Presenting with cerebral infarction following arterial occlusion
  • Treated for mechanical thrombectomy (whether performed or not)
  • Free, informed, and express consent of the patient or their relatives (emergency inclusion procedure)
  • For retrospective patients: thrombus already collected (according to the center's usual practice or for another research project).

Who cannot join

  • Patient benefiting from a legal protection measure
  • Pregnant or breastfeeding woman

Trial locations and contacts

12 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Amélie Yavchitz, MD PhD contact

0148036454 ext. +33

ayavchitz@for.paris

Jean-Philippe Désilles, MD contact

0672872906

jpdesilles@for.paris

12 sites in 1 country

France12 sites, 11 recruiting

  • CHU de Bordeaux

    Bordeaux, 33000

    Gaultier MARNAT, MD, 05 56 79 56 79 ext. + 33, gaultier.marnat@chu-bordeaux.fr

    Recruiting

  • CHU Caen

    Caen, 14000

    Charlotte Barbier, MD, 02 31 06 46 91 ext. + 33, barbier-ch@chu-caen.fr

    Recruiting

  • Chu Limoges

    Limoges, 87000

    Aymeric ROUCHAUD, Pr, 05 55 05 80 11 ext. + 33, AYMERIC.ROUCHAUD2@chu-limoges.fr

    Recruiting

  • CHRU de Nancy

    Nancy, 54000

    Benjamin GORY, Pr, 03 83 85 95 27 ext. + 33, b.gory@chru-nancy.fr

    Recruiting

  • CHU de Nantes

    Nantes, 44093

    Romain BOURCIER, MD, 02 40 16 56 08 ext. +33, Romain.BOURCIER@chu-nantes.fr

    Recruiting

  • Hôpital Lariboisière AP-HP

    Paris, 75010

    Alexis GUEDON, MD, 01 49 95 81 17 ext. + 33, alexis.guedon@aphp.fr

    Recruiting

  • Centre hospitalier Sainte-Anne

    Paris, 75014

    Olivier NAGGARA, MD, 01 45 65 80 00 ext. + 33, o.naggara@ghu-paris.fr

    Recruiting

  • Fondation Ophtalmologique A. de Rothschild

    Paris, 75019

    Jean-Philippe DESILLES, Pr, 01 48 03 69 13 ext. +33, jpdesilles@for.paris

    Recruiting

  • CHU de Rennes

    Rennes, 35000

    Completed

  • Hôpital Foch

    Suresnes, 92150

    Arthur CONSOLI, MD, 01 46 25 20 00 ext. +33, a.consoli@hopital-foch.com

    Recruiting

  • Hôpital d'Instruction des Armées Sainte-Anne

    Toulon, 83000

    Quentin HOLAY, MD, 04 83 16 21 95 ext. + 33, quentin.holay@intradel.gouv.fr

    Recruiting

  • CHRU Tours

    Tours, 37000

    Héloïse IFERGAN, MD, 02 47 47 47 47 ext. + 33, h.ifergan@chu-tours.fr

    Recruiting

Other trials in France

About this study

The recent validation of thrombectomy in addition to thrombolysis with intravenous administration of alteplase suggests a major revolution in the management of acute strokes. This treatment option also opens up a new field of research, making possible the analysis of the clot responsible for intracranial occlusion. Indeed, in about 30% of the cases, the thrombectomy procedure makes it possible to retrieve either partially or completely the clot. Previous studies have analyzed the correlation between the composition of the thrombus and the etiology of stroke. Their discordant results do not yet make it possible to distinguish a particular profile of thrombus according to etiology. Other studies have shown a correlation between the proportion of red blood cells in a thrombus and the likelihood that it is visible in MRI or cerebral scanning. More recently, one study has demonstrated a correlation between the presence of lymphocytes in the thrombus and an atheromatous etiology.

The main limitations of these studies are the small number of patients included, the high variability of conservation protocols and the absence of plasma data, which does not allow for research on the correlation between clot composition and plasma biomarkers.

Being tested
Collection of thrombus that is responsible for stroke and blood sample
Medical subject headings
Stroke

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Collection of thrombus that is responsible for stroke and blood sampleOther

    A blood sample (venous or arterial) of 10 ml will be made, on ethylene Diamine Tetra-Acetic (EDTA) tube (5 ml) and citrate (5 ml).Thrombus resulting from thrombectomy will be collected at the end of the procedure. The samples will be transferred to a biobank. Treatment efficacy, etiology and prognosis of patients will be assessed using the following criteria :

    1. TOAST score (etiology) B) TICI score (status of final recanalization) C) Extravasation of contrast agent on post-intervention CT (rupture of the blood-brain barrier :yes/no) D) Symptomatic haemorrhagic transformation corresponding to an increase > 4 of the NIHSS score due to a haemorrhagic transformation identified on brain imaging 24 hours after stroke E) Decreased NIHSS score by 8 points or NIHSS score = 0 24 hours after stroke (improved neurological status: yes/no) F) Modified RANKIN score (mRS) measured at 3 months evaluating neurological prognosis

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Correlation between the composition of the thrombus responsible for stroke, the plasma composition and the stroke characteristics (etiology, response to treatment, prognosis).

    Since this is an observational, exploratory study that correlates laboratory data (eg for thrombus: fibrinolytic, pro-oxidant activity, eg for blood: plasma fibrinolysis markers, presence of factor Von Willebrand, etc.) and clinical data (characteristics of the stroke, including the TOAST etiological score, the TICI score (TICI = thrombolysis in cerebral infarction), the NIHSS score, etc.), there is no single primary endpoint.

    Clinical data will be collected up to 3 months after stroke (Rankin score).

    Measured: 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Aug 2017
  2. Study start13 Jul 2017
  3. Primary completion12 Jul 2027 (estimated)
  4. Study completion1 Jan 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Cross-sectional
Enrolment
1,200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03268668
Sponsor's protocol ID
JDS_2017_8
Acronym
COMPO-CLOT
Status last verified
Jan 2026
First submitted
29 Aug 2017
Last updated
20 Jan 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Di Meglio L, Desilles JP, Solonomenjanahary M, Labreuche J, Ollivier V, Dupont S, Deschildre C, Maacha MB, Consoli A, Lapergue B, Piotin M, Blanc R, Ho-Tin-Noe B, Mazighi M; compoCLOT study groupdagger. DNA Content in Ischemic Stroke Thrombi Can Help Identify Cardioembolic Strokes Among Strokes of Undetermined Cause. Stroke. 2020 Sep;51(9):2810-2816. doi: 10.1161/STROKEAHA.120.029134. Epub 2020 Aug 19.

    PubMed 32811390

Questions about this trial

What is this clinical trial studying?

An observational study of Stroke, Acute and Biological Specimen Banks, run by Fondation Ophtalmologique Adolphe de Rothschild at 12 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 20 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 12 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Amélie Yavchitz, MD PhD (0148036454 ext. +33, ayavchitz@for.paris), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Correlation between the composition of the thrombus responsible for stroke, the plasma composition and the stroke characteristics (etiology, response to treatment, prognosis). (time frame: 3 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03268668, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jan 2026; AzTrials last refreshed its copy on 3 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in